Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · Real-Time Price · USD
14.45
-0.39 (-2.63%)
At close: May 12, 2025, 4:00 PM
14.39
-0.06 (-0.42%)
After-hours: May 12, 2025, 4:24 PM EDT
Delcath Systems Revenue
Delcath Systems had revenue of $19.78M in the quarter ending March 31, 2025, with 530.26% growth. This brings the company's revenue in the last twelve months to $53.85M, up 1,068.87% year-over-year. In the year 2024, Delcath Systems had annual revenue of $37.21M with 1,701.69% growth.
Revenue (ttm)
$53.85M
Revenue Growth
+1,068.87%
P/S Ratio
11.07
Revenue / Employee
$560,938
Employees
96
Market Cap
483.16M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.21M | 35.14M | 1,701.69% |
Dec 31, 2023 | 2.07M | -654.00K | -24.05% |
Dec 31, 2022 | 2.72M | -836.00K | -23.52% |
Dec 31, 2021 | 3.56M | 1.91M | 115.98% |
Dec 31, 2020 | 1.65M | 66.00K | 4.18% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DCTH News
- 3 days ago - Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 days ago - Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Delcath Systems Reports First Quarter 2025 Results and Business Highlights - Business Wire
- 14 days ago - Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer - Business Wire
- 18 days ago - Delcath Systems to Host First Quarter 2025 Earnings Call - Business Wire
- 4 weeks ago - Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma - Business Wire
- 5 weeks ago - Hospitals Experience FOMO In Adopting Delcath's PHP Treatment - Seeking Alpha
- 7 weeks ago - Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference - Business Wire